Status:
RECRUITING
Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
AuraGen Aesthetics LLC
Centre Leon Berard
Conditions:
Cancer
NGS
Eligibility:
All Genders
Brief Summary
As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing. The SONCO (Sequencing Oncology Cohort) project co...
Detailed Description
SONCO is an observational cohort study designed to assess the clinical and organizational impact of implementing genomic sequencing in oncology. It collects data from all patients referred to either o...
Eligibility Criteria
Inclusion
- Patients diagnosed with cancer and referred for high-throughput sequencing
- Sequencing pre-indication validated: Patients for whom the pre-indication for sequencing the genome, exome, and RNA has been validated by the upstream RCP (Multidisciplinary Tumor Board) since January 1, 2021.
- Consent for data reuse: Patients who have agreed to the reuse of their medical and genomic data for research purposes and have not opposed this use.
Exclusion
- Opposition to data reuse, unvalidated upstream RCP
Key Trial Info
Start Date :
July 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
3149 Patients enrolled
Trial Details
Trial ID
NCT07147465
Start Date
July 1 2025
End Date
September 30 2026
Last Update
August 29 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Leon Berard
Lyon, France, 69000
2
APHP Hôtel Dieu URC Economie de la sante /URC ECO
Paris, France, 75004
3
HOPITAL AP-HP Cochin
Paris, France, 75005